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Introduction: To offer patients with EGFR mutation–
positive advanced NSCLC appropriate EGFR tyrosine kinase
inhibitor treatment, mutation testing of tumor samples is
required. However, tissue/cytologic samples are not always
available or evaluable. The large, noninterventional diag-
nostic ASSESS study (NCT01785888) evaluated the utility of*Corresponding author.
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October 2016 ctDNA for EGFR Mutation Testing in Advanced 1683to EGFR mutation testing using local practices; designated
laboratories performed DNA extraction/mutation testing of
blood samples. The primary end point was level of
concordance of EGFR mutation status between matched
tissue/cytologic and plasma samples.
Results: Of 1311 patients enrolled, 1288 were eligible.
Concordance ofmutation status in 1162matched sampleswas
89% (sensitivity 46%, speciﬁcity 97%, positive predictive
value 78%, and negative predictive value 90%). A group of 25
patients with apparent false-positive plasma results was
overrepresented for cytologic samples, use of less sensitive
tissue testing methodologies, and smoking habits associated
with high EGFR mutation frequency, indicative of false-
negative tumor results. In cases in which plasma and tumor
samples were tested with identical highly sensitive methods,
positivepredictive value/sensitivitywere generally improved.
Conclusions: These real-world data suggest that ctDNA is a
feasible sample for EGFR mutation analysis. It is important
to conduct mutation testing of both tumor and plasma
samples in specialized laboratories, using robust/sensitive
methods to ensure that patients receive appropriate treat-
ments that target the molecular features of their disease.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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worldIntroduction
NSCLC accounts for approximately 83% of all lung
cancers, and most patients present with advanced disease
at diagnosis.1 Adenocarcinoma (ADC), which is among the
most commonof theNSCLChistological subtypes, hasbeen
shown to be associated with activating mutations in the
EGFR gene in 13% of European and 47% of Japanese pa-
tients (corresponding rates for non-ADC 5% and 7%,
respectively).2 Response to EGFR tyrosine kinase in-
hibitors (TKIs) is acknowledged to be greater in patients
with tumorsharboring activatingmutations in the tyrosine
kinase domain of the EGFR gene versus wild-type EGFR.3
Furthermore, EGFR TKIs have demonstrated efﬁcacy su-
perior to that of doublet chemotherapy in patients with
EGFR mutation–positive advanced NSCLC.4–8 Clinical
guidelines9,10 and several working groups11,12 thus advo-
cate mutation testing of tumor sample DNA from patients
with nonsquamous advanced NSCLC to conﬁrm suitability
for EGFR TKI treatment. However, tissue/cytologic sam-
ples arenot always available or evaluable for diagnosis and
mutation testing, leaving some patients unable to have the
EGFRmutation status of their tumors determined.13Several studies have demonstrated that it is feasible
to assess EGFR mutation status by using circulating free
tumor-derived DNA (ctDNA), which can be isolated from
the plasma or serum of patients with NSCLC.4,14 Indeed,
nucleic acid released from tumor cells into the circula-
tion represents an alternative source of tumor-derived
DNA, an approach referred to as liquid biopsy.13 Indic-
ative of the clinical relevance of ctDNA in mutation
analysis, the presence of EGFR mutations in ctDNA has
been found to predict response to EGFR TKIs7,13,15;
similar objective response rates and progression-free
survival have also been observed between patients
with EGFR mutation–positive NSCLC detected by testing
of tissue/cytologic samples and patients with EGFR
mutations detected in their ctDNA.4 Indeed, an amend-
ment to the summary of product characteristics for the
EGFR TKI geﬁtinib stating that ctDNA may be used for
mutation analysis of NSCLC when tumor samples are
unavailable16 was adopted by the Committee for Me-
dicinal Products for Human Use in September 2014.
As ctDNA analysis is technically challenging, it is
important that the accuracy, suitability, and feasibility of
use of ctDNA for mutation analysis in clinical practice be
established. In the open-label IFUM study of white pa-
tients with EGFR mutation–positive NSCLC, between 652
evaluable matched tissue/cytologic and plasma (ctDNA)
samples, mutation status concordance was 94%,
demonstrating a high accuracy of ctDNA-based mutation
testing with respect to tissue-based testing.4 However,
there is a need to conﬁrm such ﬁndings outside of the
controlled clinical trial environment to improve local
diagnostic practice, enable wider access to ctDNA mu-
tation testing, and provide more patients with the op-
portunity to receive therapies personalized to the
mutation status of their tumors. The large, multicenter,
noninterventional, diagnostic ASSESS study
(NCT0178588) investigated the utility of ctDNA for EGFR
mutation testing in a real-world diagnostic setting.Materials and Methods
Study Design and Participants
Eligible patients were those at least 18 years of age
(20 years in Japan) with histologically/cytologically
conﬁrmed, systemic treatment-naive, locally advanced
NSCLC (stage IIIA/B according to the American Joint
Committee on Cancer staging system) unsuitable for
curative treatment or chemoradiotherapy or with met-
astatic disease (stage IV) and those with recurrent dis-
ease after previous curative treatment (resection and/or
adjuvant chemotherapy). Provision of a diagnostic
tissue/cytologic sample and a fresh blood (plasma)
sample at enrollment was mandatory. The blood sample
was taken before initiation of any treatment.
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concordance between EGFR mutation status obtained
by tissue/cytologic testing and that obtained by blood
(plasma)-based testing. Secondary end points included
EGFR mutation testing practices and mutation frequency
and correlations between mutation status and de-
mographic data/disease status and treatment decisions
after mutation testing (not reported).
All patients provided written, informed consent. Study
approval was obtained from the independent ethics
committees at each institution. The study was conducted
in accordance with the Declaration of Helsinki, the In-
ternational Conference on Harmonization/Good Clinical
Practice, applicable regulatory requirements for non-
interventional studies, and AstraZeneca’s policy on
bioethics and human biological samples.
Procedures
EGFR mutation testing and results data for tumor
samples obtained before enrollment in ASSESS were
used where available (see Fig. 1A). For tests conducted
in ASSESS, diagnostic tissue/cytologic samples were
subjected to EGFR mutation testing as per local practices
after histopathological review (WHO classiﬁcation17) to
ensure that samples were adequate for use. Each patient
provided a 10-mL blood sample, which was pro-
cessed to plasma, frozen, and transported to designatedA
B
Figure 1. Mutation testing methods used for tissue/cytologic
population). Other refers to Fragment Length Analysis/PNA-L
peptide nucleic acid-locked nucleic acid; RGQ, Rotor-Gene Q.laboratories for mutation testing. In Europe, 43 aca-
demic, hospital, and commercial laboratories performed
the tissue/cytologic testing and ﬁve central/regional
expert laboratories were used for blood-based testing. In
Japan, two commercial laboratories were used for both
tissue/cytologic and blood-based testing.
Outcomes
Testing methodologies, sample types and availability,
testing turnaround time, and testing success rate/
mutation detection rate were captured to assess
EGFR mutation testing practices. Concordance of EGFR
mutation status between matched tissue/cytologic and
plasma samples was assessed by using the following:
concordance rate; sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value
(NPV) (Supplementary Table 1); and exact two-sided
95% conﬁdence interval (CI).
Statistical Analyses
Concordance of EGFR mutation status between
matched tissue/cytologic and plasma samples was
calculated for the evaluable population (all eligible pa-
tients with known tumor [tissue/cytologic] and plasma
sample mutation status). The sample size of ASSESS
was calculated to allow accurate determination of sen-
sitivity between tumor- and blood-based testing. For 100(A) and plasma (B) samples in Europe and Japan (enrolled
NA PCR Clamp. PCR, polymerase chain reaction; PNA-LNA,
Table 1. Patient Demographics (Enrolled Population)
Characteristic
Europe Japan Overall
(n ¼ 997) (n ¼ 291) (n ¼ 1288)
Mean age ± SD 65.4 ± 9.74 70.2 ± 9.0 66.5 ± 9.8
Men, n/N (%) 675 of 997 (68) 192 of 291 (66) 867 of 1288 (67)
Race, n/N (%)
White 976 of 997 (98) 0 of 291 (0) 976 of 1288 (76)
Asian 5 of 997 (1) 291 of 291 (100) 296 of 1288 (23)
WHO performance status, n/N (%)
0 388 of 997 (39) 114 of 291 (39) 502 of 1288 (39)
1 453 of 997 (45) 117 of 291 (40) 570 of 1288 (44)
2 136 of 997 (14) 37 of 291 (13) 173 of 1311 (13)
3 17 of 997 (2) 18 of 291 (6) 35 of 1288 (3)
4 3 of 997 (0) 5 of 291 (2) 8 of 1288 (1)
Smoking status
Never-smoker, n/N (%) 174 of 996 (17) 78 of 291 (27) 252 of 1287 (20)
Pack-years, median 40.0 45.0 40.0
Note: Pack-years ¼ (number of cigarettes smoked per day  number of years smoked)/20.
October 2016 ctDNA for EGFR Mutation Testing in Advanced 1685patients with EGFR mutation-positive NSCLC, if the
sensitivity was 50%, the 95% CI would be expected to be
40% to 60%. Assuming a 10% prevalence of EGFR mu-
tations in Europe, it was estimated that 1000
patients should be tested to obtain 100 with EGFR mu-
tation–positive NSCLC. As an independent replication,
sensitivity was obtained in patients from Japan;Figure 2. Patientassuming a 30% prevalence of EGFR mutations in Japan,
it was estimated that 300 patients should be tested to
obtain 100 with EGFR mutation–positive NSCLC.
EGFR mutation testing practices (enrolled popula-
tion) and EGFR mutation frequency (evaluable tumor/
plasma populations) were summarized by using appro-
priate descriptive statistics.ﬂow diagram.
Table 2. EGFR Mutation Frequency by Sample Type, Region,
and Histologic Subtype (Population with Evaluable Tissue/
Cytologic and/or Plasma Samples)
Characteristic
EGFR mutation frequency
Tissue/Cytologic
Samples Plasma
n/n (%) n/n (%)
Overall 191 of 1184 (16) 119 of 1263 (9)
Country
Europe 105 of 903 (12) 82 of 972 (8)
Japan 86 of 281 (31) 37 of 291 (13)
Histological subtype
ADC 177 of 907 (20) 109 of 952 (11)
Non-ADC 12 of 257 (5) 9 of 288 (3)
TNM stage
IIIA 5 of 66 (8) 3 of 75 (4)
IIIB 3 of 105 (3) 2 of 119 (2)
IV 183 of 1006 (18) 114 of 1063 (11)
TNM stage IV
M1a 57 of 235 (24) 17 of 252 (7)
M1b 82 of 490 (17) 67 of 528 (13)
EGFR mutation subtype
Exon 19 deletions 97 of 191 (51) 68 of 119 (57)
Exon 19 deletions þ T790M 0 of 191 (0) 0 of 119 (0)
L858R 73 of 191 (38) 38 of 119 (32)
L858R þ T790M 0 of 191 (0) 2 of 119 (2)
T790M only 0 of 191 (0) 3 of 119 (3)
T790M þ othera 1 of 191 (1) 1 of 119 (1)
Otherb 20 of 191 (10) 7 of 119 (6)
aAny other mutation that occurred in combination with T790M that is not
L858R or Exon 19 deletion.
bThis category included double mutations not speciﬁed.
ADC, adenocarcinoma.
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Patients
From April 11, 2013, to April 17, 2014, a total of 1311
patients were enrolled (Table 1), 1288 of whom were
eligible (Fig. 2). A total of 23 patients were enrolled in
error (they did not fulﬁl the inclusion/exclusion criteria)
and were not included in the ﬁnal analysis
(Supplementary Table 2).
Sampling Methodologies and EGFR Mutation
Testing Practices
Tissue/cytologic samples were mostly collected dur-
ing current diagnosis (Supplementary Fig. 1A) and most
often sampled from the primary tumor (Supplementary
Fig. 1B). The most frequent sampling sites were the
lungs/lymph nodes (Supplementary Fig. 1C). Bronchos-
copy was the most frequently used sample collection
method (Supplementary Fig. 1D). A range of mutation
testing methods for tissue/cytologic samples (>10) were
observed in Europe versus only two methods in Japan
(Fig. 1A). The mutation testing methods observed for
plasma were limited and differed between Europe and
Japan (Fig. 1B).
The median EGFR test turnaround time for tissue/
cytologic samples was 11 days for Europe (95% CI:
14.0–17.3) and 8 days for Japan (95% CI: 8.2–14.1);
mutation testing success rates were high in both Europe
(98%) and Japan (<100%). Mutation tests were not
performed on the tissue/cytologic samples of 110 pa-
tients and results were not obtained from the tested
samples of 17 patients. The most frequent reason for not
testing was insufﬁcient material provided (60% [47 of
78 responses to the question] in Europe and 56% [ﬁve of
nine] in Japan). There were no obvious differences in
sampling methods between evaluable and nonevaluable
tissue/cytologic samples.
EGFR Mutation Frequency
The overall EGFR mutation frequency was 16% for
evaluable tissue/cytologic samples and 9% for evaluable
plasma samples (Table 2). Consistent with previous re-
ports,2 in Europe, 14% of ADC tissue/cytologic samples
(99 of 712) and 3% of non-ADC samples (six of 180)
were EGFR mutation–positive. In Japan, 40% of ADC
tissue/cytologic samples (78 of 195) and 8% (six of 77)
of non-ADC samples were EGFR mutation–positive.
Concordance of EGFR Mutation Status between
Matched Tissue/Cytologic and Plasma Samples
Overall concordance of mutation status was 89%
(sensitivity 46%, speciﬁcity 97%, PPV 78%, and NPV
90%) (Table 3). An EGFR mutation–positive result in
plasma and mutation-negative result in tissue/cytologictesting were observed in samples from 25 patients
(false-positive rate 22%); the demographics and
sampling/mutation testing methodologies associated
with these patients are summarized in Supplementary
Table 3. False-negative results were obtained for 102
patients (10%).
When tissue/cytologic and plasma samples were
tested with identical, sensitive methods (Qiagen ther-
ascreen EGFR Rotor-Gene Q Polymerase Chain Reaction
(PCR) Kit, Peptide Nucleic Acid–Locked Nucleic Acid PCR
Clamp [Qiagen, Manchester, UK], Roche cobas EGFR Mu-
tation Test [RocheMolecular Diagnostics, Pleasanton, CA],
or Cycleave [Takara Bio Inc., Kusatsu, Japan]), the PPV and
sensitivity were generally improved (see Table 3).
Furthermore, in a subset of 94 Japanese patients,
sensitivity increased from an initial result of 17% (ﬁve of
29) to 52% (15 of 29) when samples that had originally
had ctDNA extracted using the Qiagen QIAamp MinElute
Virus Spin Kit for DNA (400 mL plasma) had extraction
repeated using the Qiagen QIAamp Circulating Nucleic
Acid Kit (3 mL plasma) speciﬁcally designed to
isolate smaller, fragmented DNA, even though the same
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October 2016 ctDNA for EGFR Mutation Testing in Advanced 1687detection method (peptide nucleic acid–locked nucleic
acid PCR Clamp) had been used. Including the newer
Japanese subset data in the overall data increased
the concordance rate (90% [1036 of 1158]), sensitivity
(50% [97 of 194]), PPV (80% [97 of 122]), and NPV
(91% [939 of 1036]).
Discussion
To our knowledge, ASSESS is the most comprehen-
sive study of real-world EGFR mutation testing practices
in Europe and Japan. ASSESS was designed to evaluate
how data obtained using local practices for tissue/cyto-
logic and plasma sample testing compare with data
obtained from well-controlled clinical testing that is
generally performed in a single expert laboratory.
The mutation status concordance observed between
1162 matched tissue/cytologic and plasma samples
(89%) suggests that ctDNA is a feasible sample for real-
world EGFR mutation analysis if robust/sensitive DNA
extraction and mutation analysis methodologies are
used. ctDNA comprises less than 1% of total circulating
free DNA18; including data from the subset of patients
who had DNA reextracted with an optimized method
increased the overall concordance rate and sensitivity.
The low PPV (78%) raised a concern that some of the
plasma EGFR mutation results might be false positives,
and 25 patients for whom testing yielded apparent false-
positive plasma results were identiﬁed (Supplementary
Table 3). This group was overrepresented for cytologic
samples, which may not be representative of the disease,
and/or the use of less sensitive DNA sequencing meth-
odologies (56% of these 25 tumor samples were tested
by DNA sequencing/pyrosequencing versus 25% of
samples from the overall population [305 of 1201]). In
addition, 80% of these patients were never-, former, or
light smokers, a subgroup in which a higher EGFR mu-
tation frequency is expected. Furthermore, in Europe,
the EGFR mutation frequency by DNA sequencing/
pyrosequencing of tissue/cytologic samples was 10%
(37 of 370) versus 15% (68 of 465) for all other
methods combined, suggesting that DNA sequencing/
pyrosequencing may have missed some of the EGFR
mutations present. This ﬁnding is in agreement with
results of external quality assessment studies that have
revealed a high rate of genotyping errors in Europe,
where less sensitive techniques are still frequently
used.19,20 Overall, these data suggest that the low PPV
was due to false-negative results in tumor rather than to
false-positive results in plasma. False-negative results
can occur because of tumor heterogeneity, inexperience,
or use of methods with low sensitivity.
In contrast, it is clear that a negative result in plasma
may be incorrect (false-negative), as ctDNA mutation
analysis may not pick up EGFR mutations in all patients
1688 Reck et al Journal of Thoracic Oncology Vol. 11 No. 10who carry them in their tumors. The sensitivity of
plasma tests, which is indicative of how likely they are
to accurately detect EGFR mutations, varied (36%–
100%) between countries. ASSESS revealed substantial
differences within/between Europe and Japan in the
mutation testing methodologies used, reﬂecting differ-
ences in available and/or accessible equipment and
knowledge, which may contribute to this variation.
However, overall sensitivity (46%) was markedly lower
than the pooled sensitivities reported in two recent
meta-analyses of concordance of EGFR mutation status
between matched tissue/cytologic and plasma samples
(62%–67%).21,22
Caution is advised when comparing data from clin-
ical trials, in which testing is generally well controlled
and performed in a single central laboratory, with the
real-world ASSESS data. Of note, the concordance rate
of 94% (sensitivity 66%, speciﬁcity 100%, PPV 99%,
and NPV 94%) reported for IFUM was higher than in
ASSESS.4 Likewise, the sensitivity and PPV were higher
in FASTACT-223 (75% and 94%, respectively) and
sensitivity in the EURTAC study24 was 78%. IFUM uti-
lized the Qiagen therascreen EGFR Rotor-Gene Q PCR
Kit for mutation analysis of matched tissue/cytologic
and plasma samples. Interestingly, the ASSESS concor-
dance data for matched tissue/cytologic and plasma
samples tested with the therascreen kit were highly
consistent with that of IFUM (concordance 95% [131 of
138], sensitivity 73% [16 of 22], speciﬁcity 99% [115 of
116], PPV 94% [16 of 17], and NPV 95% [115 of 121]).
This conﬁrms the ﬁndings of the IFUM study,4 which
indicated that when an EGFR mutation is detected in
ctDNA, the result can be trusted and a prescriber
can conclude that the patient is likely to beneﬁt from
TKI therapy.
In real-world practice, test sensitivity may be further
complicated by the different stage/differentiation of the
disease,25 which likely inﬂuence release of ctDNA into
blood. In ASSESS, a higher frequency of EGFR mutations
was observed in the plasma of patients with M1b disease
(13%) versus M1a disease (7%) despite the EGFR mu-
tation frequency in tumor being similar in these
two groups, which is consistent with the hypothesis of
greater release of ctDNA in patients with distant me-
tastases. It must be noted that analysis of ctDNA may
allow identiﬁcation of mutations in heterogeneous tu-
mors that could carry a speciﬁc variant in only a minor
tumor clone (i.e., beyond the “biopsy zone”). However,
although plasma-based testing requires standardization
as a technique under relatively early investigation, the
ASSESS results suggest that further improvements in
mutation analysis of tissue/cytologic samples are still
required to reduce the occurrence of false-negative
results.In IFUM, 19% of patients had nonevaluable tissue/
cytologic samples for reasons including low tumor
content, insufﬁcient sample quality/quantity, poor/
inappropriate ﬁxation, and no DNA.4 In this respect, ac-
curate and accessible ctDNA mutation testing to address
the unmet need in patients without an available/evalu-
able tumor sample will be important to enable more
patients to receive therapies personalized to the muta-
tion status of their tumor.
Conclusions
These ASSESS real-world data suggest that ctDNA is a
feasible sample for EGFR mutation analysis when tumor
samples are unavailable. It is important to conduct
mutation testing of both tumor and plasma samples in
specialized laboratories, using robust and sensitive
mutation testing methods to ensure accuracy of results.
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